Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Director Arthur F. Ryan sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $429.34, for a total transaction of $858,680.00. Following the sale, the director now directly owns 36,500 shares in the company, valued at $15,670,910. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 2.00% during midday trading on Wednesday, hitting $420.08. 815,499 shares of the stock were exchanged. The stock has a market cap of $44.04 billion, a P/E ratio of 61.29 and a beta of 1.79. Regeneron Pharmaceuticals Inc. has a one year low of $325.35 and a one year high of $592.59. The stock’s 50-day moving average price is $382.11 and its 200 day moving average price is $387.86.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.40. The business earned $1.22 billion during the quarter, compared to the consensus estimate of $1.29 billion. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.47 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current year.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

A number of brokerages have commented on REGN. Cowen and Company reissued a “hold” rating and issued a $430.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 5th. Roth Capital reissued a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, September 23rd. Vetr downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and set a $422.08 price objective on the stock. in a research report on Wednesday, July 27th. Piper Jaffray Cos. set a $447.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, October 13th. Finally, Canaccord Genuity set a $450.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, November 6th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $471.05.

A number of large investors have recently bought and sold shares of REGN. Winslow Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $291,760,000. FMR LLC increased its stake in Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock valued at $3,288,642,000 after buying an additional 795,283 shares during the last quarter. Capital World Investors increased its stake in Regeneron Pharmaceuticals by 6.6% in the third quarter. Capital World Investors now owns 7,810,538 shares of the biopharmaceutical company’s stock valued at $3,139,992,000 after buying an additional 483,912 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $87,319,000. Finally, BlackRock Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 136.0% in the second quarter. BlackRock Investment Management LLC now owns 403,418 shares of the biopharmaceutical company’s stock valued at $140,886,000 after buying an additional 232,471 shares during the last quarter. 68.58% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.